1129 |
CHOLINERGIC RECEPTOR MUSCARINIC 2 |
CHRM2 |
HM2 |
118493 |
1951 |
ENSG00000181072 |
OTTHUMG00000155658 |
P08172 |
ACM2_HUMAN |
MUSCARINIC ACETYLCHOLINE RECEPTOR M2. [SOURCE:UNIPROT/SWISSPROT;ACC:P08172] |
MUSCARINIC ACETYLCHOLINE RECEPTOR M2 |
PA111 |
T46185 |
Target Main Class | Receptors |
Target Subclass | Rhodopsin |
Transmembrane Helix Count | 6 |
Target Subclass | GPCR |
Human Readable Name | DRUGGABLE GENOME |
Target Class | Receptors |
Interpro Acc | IPR000276 |
Human Readable Name | G PROTEIN COUPLED RECEPTOR |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Name | GPCR, rhodopsin-like, 7TM |
Interpro Short Name | 7TM_GPCR_Rhodpsn |
Uniprot Status | Swiss-Prot |
Interpro Type | Family |
Gene Biotype | PROTEIN_CODING |
G PROTEIN COUPLED RECEPTOR |
DRUGGABLE GENOME |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | AA-2010 |
Novel drug target | Established target |
Trial Name | AP-1034,Anturol |
partial agonist (activating) |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | rocuronium bromide,Esmeron, Zemuron, Eslax |
Novel drug target | Established target |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Muscarinic acetylcholine receptor M2 antagonist |
Trial Name | inhaled atropine |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | ipratropium bromide + albuterol sulfate,DuoNeb |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | Solifenacin succinate, YM-905,Vesicare |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | tiotropium bromide,Spiriva |
Novel drug target | Established target |
antagonist (inhibitory) |
Novel drug target | Established target |
Trial Name | - |
antagonist (inhibitory) |
Mechanism of Interaction | Muscarinic acetylcholine receptor M2 antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Muscarinic acetylcholine receptor M2 antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Muscarinic acetylcholine receptor M2 antagonist |
Direct Interaction | yes |
agonist (activating) |
Direct Interaction | yes |
Mechanism of Interaction | Muscarinic acetylcholine receptor M2 agonist |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Muscarinic acetylcholine receptor M2 antagonist |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Muscarinic acetylcholine receptor M2 antagonist |
agonist (activating) |
Novel drug target | Established target |
Trial Name | THVD-201 |
antagonist (inhibitory) |
Mechanism of Interaction | Muscarinic acetylcholine receptor M2 antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Muscarinic acetylcholine receptor M2 antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Muscarinic acetylcholine receptor M2 antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | Silenor (SO-101) |
Novel drug target | Established target |
antagonist (inhibitory) |
Mechanism of Interaction | Muscarinic acetylcholine receptor M2 antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Trial Name | Aclidinium |
Novel drug target | Established target |
antagonist (inhibitory) |
Mechanism of Interaction | Muscarinic acetylcholine receptor antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
n/a |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Mechanism of Interaction | Muscarinic acetylcholine receptor antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Muscarinic acetylcholine receptor M2 antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Trial Name | ALKS 3831 |
Trial Name | OREX-003, olanzapine plus zonisamide SR |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
CHRM2 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
CHRM2 | Display Id |
MUSCARINIC ACETYLCHOLINE RECEPTOR M2. [SOURCE:UNIPROT/SWISSPROT;ACC:P08172] | Description |
ENSG00000181072 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
CHRM2 | Gene Symbol |
Target Class | Receptors |
Target Subclass | GPCR |
Target Subclass | Rhodopsin |
P08172 | Uniprot Accession |
MUSCARINIC ACETYLCHOLINE RECEPTOR M2 | Uniprot Protein Name |
CHRM2 | Uniprot Gene Name |
Interpro Acc | IPR000276 |
Human Readable Name | G PROTEIN COUPLED RECEPTOR |
Uniprot Evidence | 1: Evidence at protein level |
G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME |
1129 | Entrez Gene Id |
P08172 | Uniprot Accession |
ACM2_HUMAN | Uniprot Id |
Target Main Class | Receptors |
Target Subclass | Rhodopsin |
Transmembrane Helix Count | 6 |
PA111 | PharmGKB ID |
CHRM2 | GENE_SYMBOL |
Muscarinic acetylcholine receptor M2 | UNIPROT |
ENSG00000181072 | Gene Symbol |
CHRM2 | Ensembl Id |
DRUGGABLE GENOME |
1129 | Gene ID |
HM2 | dGene Synonym |
G PROTEIN COUPLED RECEPTOR |
CHRM2 | TTD Gene Abbreviation |
T46185 | TTD Target ID |